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OBJECTIVES: Cerner has developed the St John’s Sepsis Alert, an evidence-based 
real-time algorithm that alerts clinicians to the presence of the Systemic 
Immune Response Syndrome or sepsis. Using simulation, we estimated the 
Alert’s performance and determined the optimal cut-offs for ~17 included 
quantitative parameters (e.g., blood pressure). METHODS: We estimated the 
operating characteristics of the alert by applying its logic to 3 years of real-world 
data on adults from Cerner Health Facts, a time-stamped database extracted from 
electronic medical records. We evaluated the base-case and performed a 10,000-
iteration uncertainty analysis. Each run used a different set of thresholds, each 
drawn randomly from the range of reasonable values using a Latin hypercube 
sampling design under the assumption of an independently distributed joint 
beta distribution. Each run provided a point on the Receiver Operator 
Characteristic curve. We constructed an extended dominance curve from the 
resulting point cloud and determined the optimal values as those associated 
with that curve. RESULTS: Data from ~69,000 hospitalizations with a 5% 
incidence of sepsis were available. Using baseline values for the Alert, we 
estimated a Sensitivity of 56%, Specificity of 90%, Positive Predictive Value of 
22%, and Negative Predictive Value of 98%. The uncertainty analysis found that 
10 sets of cut-offs dominated all the others. The C-statistics for these ranged 
from 67% to 75%, Sensitivity from 39% to 73%, Specificity from 96% to 76%, PPV 
33% to 13%, NPV 95% to 98%, and the posterior probability of sepsis increased 
from 2.4- to 7-fold. The most accurate thresholds were not necessarily optimal 
for implementation; certain sets with only slightly lower C-statistics greatly 
decreased false positive rates. CONCLUSIONS: Simulation can usefully inform in 
the design of clinical algorithms prior to implementation. Examining a range of 
thresholds can identify statistical optimality and characterize trade-offs to 
deviating from it.  
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EVALUATING THE COST-EFFECTIVENESS OF MULTICOMPONENT 
REHABILITATION GUIDELINES  
Mewes JC, Steuten LMG, IJzerman MJ, van Harten WH 
University of Twente, Enschede, The Netherlands  
OBJECTIVES: The Dutch guideline for cancer rehabilitation recommends patients 
to engage in multicomponent interventions, i.e. several single interventions 
combined into a rehabilitation programme. To perform a health economic 
evaluation of this guideline, data on the cost-effectiveness of these 
multicomponent interventions is required. However, to date, the interventions´ 
(cost-)effectiveness is almost exclusively assessed for the single interventions, 
rather than for the multicomponent intervention, which challenges the health 
economic analysis of the multicomponent interventions. The objective of this 
study was to identify or develop a method that allows to deduct the cost-
effectiveness of multicomponent interventions from published data of the single 
interventions. METHODS: We searched the literature for articles offering a 
method or ideas for the development of a method for assessing the cost-
effectiveness of multicomponent interventions on the basis of data on the single 
interventions. The cost-effectiveness gap analysis method, which can be used for 
assessing the maximum cost of an intervention given a certain willingness-to-
pay, was identified as suitable and was further developed to allow assessing if a 
multidimensional programmes is cost-effective, based on the (cost-)effectiveness 
data of the single interventions. RESULTS: Cost-effectiveness gap analysis was 
identified in the literature as being a suitable method, with further refinement. 
We suggested to first calculate the costs of all interventions. Given the 
effectiveness of one intervention it is then possible to estimate how much 
additional effectiveness a second (or any subsequent) intervention would have to 
provide so that the multicomponent intervention remains cost-effective, given a 
range of ceiling ratios. Recommendations for methods for estimating the 
additional effect of subsequent interventions were deducted from the literature 
identified. CONCLUSIONS: We suggest estimating the cost-effectiveness of the 
combined interventions as recommended in clinical guidelines by performing a 
refined cost-effectiveness gap analysis method.  
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OBJECTIVES: Along with uncertainty around reimbursement decisions, one 
should determine the worth of additional research to reduce the probability of 
making wrong decisions. Value of information analysis (VOI) provides an explicit 
framework to inform future research. The objectives of this research were to 
assess published evidence of VOI and to evaluate its impact on decision making 
and research agendas. METHODS: A literature review was conducted in MEDLINE 
and EMBASE to collect studies with VOI applications published until November 
2012. Data extracted included study indication, year, country, sponsorship, type 
of VOI analysis, research impact and quality of the study. HTA guidelines of 
developed countries were checked and country experts were approached to 
discuss the relevance of VOI. RESULTS: One hundred studies with VOI 
applications were identified. Amongst these, cancer was the most popular 
indication (25%) and the majority had a UK perspective (49%). The number of 
publications gradually rose after 2005 but remained steady since 2009. Rarely, 
studies were sponsored by industry (8%). Expected value of perfect (parameter) 
information (EVP(P)I) was reported in 92% (59%) of the articles, respectively. Only 
12% of articles reported expected value of sample information (EVSI) and 4% 
reported expected value of perfect implementation (EVPIM). Finally, no actual 
implication on future research had been reported. Only the UK and Netherlands 
recommend the use of VOI in the HTA guideline. However VOI is not a formal 
requirement in the manufacturer/sponsor submission of evidence to NICE or 
CvZ. All experts reported lack of influence of VOI in research decision. 
CONCLUSIONS: The application of VOI to inform HTA and research is limited. 
Even in the UK and Netherlands, where VOI analysis is recommended in the HTA 
guidelines.  
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PREDICTION OF MORTALITY IN THE PRESENCE OF TIME-DEPENDED 
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OBJECTIVES: We want to develop a parametric model to predict mortality for 
future patients with a disease that have specific demographic and clinical 
characteristics while considering patient trajectories over time for a set of 
biomarkers, which are critical predictors of disease progression. This is an 
important tool for many health economic projections. METHODS: In time-to-
event studies, longitudinal measures are collected for important disease 
progression biomarkers. Using only the last available value of these measures in 
survival models discards important information from the longitudinal evolution. 
We used data from a 3-year observational study to estimate the covariate 
coefficients in a Cox-proportional hazards model in the presence of time-
dependent biomarkers via SAS® PHREG. In addition, we applied a Weibull 
accelerated failure time model to estimate the scale/shape of a parametric 
survival distribution using SAS®LIFEREG, which, unlike PHREG, does not allow for 
direct incorporation of longitudinal measures. In developing the final prediction 
model, we combined the coefficients from PHREG and the scale/shape from 
LIFEREG to compute the probability of survival. RESULTS: By applying the 
Weibull model without considering patient trajectories over time, we predicted a 
3-year survival rate of 55.1%. However, the hybrid combination approach of the 
Cox/Weibull model, predicted a more accurate 3-year survival rate of 46.7%, 
which fell within the confidence bounds of the original observational study. 
CONCLUSIONS: Ignoring the additional variability of patient trajectories over 
time, when modeling survival, can lead to biased estimates. We have 
implemented a hybrid approach by which we incorporated the impact of time-
dependent biomarkers of the disease along with the scale/shape of a parametric 
survival distribution to more accurately project survival time in health economic 
modeling.  
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OBJECTIVES: It is not uncommon to have heterogeneous patient populations in 
clinical trials while lacking established biomarkers/factors to identify 
heterogeneity. In estimating average survival time, a critical component in 
economic models, extrapolation of limited trial data is often necessary and 
standard parametric survival models are regularly used without considering 
population heterogeneity. Our project was to introduce mixture modeling that 
incorporated population heterogeneity. METHODS: Heterogeneous survival data 
were simulated. Mixture models, besides standard survival models, were applied 
to address population heterogeneity via Bayesian inference, where clinical 
inputs (e.g., survival of one sub-population is longer than the other) can also be 
incorporated. The model fit was evaluated and the average survival was 
estimated. RESULTS: Two-hundred patient level survival data were simulated 
from a mixture of two exponentials with average survival of 3 (30% of patients) 
and 0.6 year respectively and overall average survival of 1.32 years. The 
simulation was run 100 times. For each dataset, Bayesian inference was based on 
10000 iterations after 1000 burn-in. In one exercise, the standard approach, 
including exponential, Weibull and lognormal models, and a mixture of two 
exponentials were applied. The mixture model provided a good fit per DIC and 
the estimated proportion was 0.372 (SD: 0.13). The estimates for average survival 
were compared across methods (true mean: 1.32; exponential: 1.238 [SD: 0.142], 
Weibull: 1.260 [SD: 0.151], lognormal: 1.760 [SD: 0.311]; exponential mixture: 1.311 
[SD: 0.178]). The extension to mixture models with different components 
(number or structure) could be implemented. CONCLUSIONS: The mixture 
modeling could potentially improve the estimates for average survival time in 
heterogeneous populations. Though this doesn’t apply in every situation, 
heterogeneity should be considered based on clinical inputs, and tools that 
address heterogeneity from both clinical and statistical perspectives should 
continue to be developed to support survival modeling.  
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A METHOD TO ESTIMATE DISEASE-STAGE-SPECIFIC SURVIVAL USING DATA 
OBTAINED FROM A PREVALENT COHORT  
Sabatelli L 
GLOB MOD, Barcelona, Spain  
OBJECTIVES: Technical, ethical, and practical reasons may hamper efforts to 
understand how survival rates of treated and untreated individuals change as a 
result of disease progression. This is a rather general problem that concerns 
communicable and non communicable diseases alike. In certain instances, the 
only available survival information refers to prevalent (as opposed to incident) 
cohorts, where individuals are randomly selected and enrolled irrespectively of 
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their disease stage. The methodological framework here presented uses 
prevalent cohort survival data to reconstruct stage-specific survival rates, as 
they would be if obtained from an incident cohort. METHODS: This approach 
assumes proportional hazards and, under certain caveats, can be generalized to 
non-proportional hazards. Through a piece-wise back calculation approach 
recent survival data are fed and integrated into the model to calculate survival at 
earlier stages of the disease, this allows the reconstruction of the survival 
probability as a function of the time elapsed from the onset of illness. This 
method is then generalized to allow comparison between ‘placebo’ and 
‘treatment’ prevalent-cohorts. RESULTS: The method is very general and can be 
applied to a variety of cases. As an example, the only published data on an 
untreated tuberculosis prevalent cohort is used to infer the actual mortality rates 
of untreated tuberculosis through the course of the illness. The results show that 
mortality is highest within the first two years of illness, declining dramatically 
immediately after and increasing again to intermediate rates after one year, 
suggesting population heterogeneity with respect to the risk of dying from 
tuberculosis-related illness. In general, if sufficient data on a ‘placebo’ and on a 
‘treatment’ cohorts is available, this method can be used to infer the potential 
stage-specific effectiveness of a treatments. CONCLUSIONS: Under specific 
modeling assumptions, incident-cohort survival and treatment effect can be 
inferred from prevalent-cohort studies.  
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OBJECTIVES: Post-menopausal women are under-diagnosed in claims data even 
though they exhibit symptoms. Probabilistic linkage was conducted between 
claims data and The University of Michigan Women’s Registry data to control for 
post-menopausal symptoms as risk factors in the analysis. METHODS: Women 
with a menopause diagnosis who used estrogen only hormone therapy (HT) were 
selected from the registry data. A separate group of patients age 45 or older who 
were prescribed estrogen only HT was selected from a large U.S. claims database. 
Logistic regression was conducted to calculate the propensity score for each 
patient, controlling for women’s health-related comorbidities in each population. 
Patients with the closest propensity score from each group were matched, and 
the menopause symptoms of Registry patients were added to the claims records 
of the corresponding matched patients in the claims data. This linkage process 
was repeated 250 times, and the mean and 95% confidence interval (CI) of health 
care costs during the follow-up period were calculated. RESULTS: Among 2771 
women, 16% (N=443) were diagnosed as post-menopausal. Of this subset, 83 
patients prescribed estrogen only HT were selected. After probabilistic linking 
with the 20,020 selected women from the claims database, 80 patients from each 
population were matched. The average cost of patients with at least one 
symptom was much higher compared to patients without symptoms ($13,570 
[95% CI: $13,459-$13,680] vs. $3,391 [95% CI: $3,345-$3,436], p-value<0.001). Cost 
differences were mainly from inpatient ($1,997 [95% CI: $1,925-$2,070], p-
value<0.001 vs. $247 [95% CI: $239-$254, p-value<0.001), physician visit ($967 [95% 
CI: $961-$974], p-value<0.001 vs. $248 [95% CI: $246- $251], p-value<0.001), and 
pharmacy costs ($3,676 [95% CI: $3,648-$3,704], p-value<0.001 vs. $903 [95% CI: 
$890-$916], p-value<0.001). CONCLUSIONS: The study suggests that post-
menopausal symptoms are important risk factors to control when assessing 
health care costs in claims data. Probabilistic linkage can bridge the gap between 
claims and registry data information.  
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OBJECTIVES: To evaluate the equivalence of electronic and paper versions of the 
Psoriasis Symptom Inventory (PSI) and examine measurement properties of the 
electronic version. METHODS: In a prospective, randomized, cross-over, non-
interventional study in adult subjects (age ≥ 18 years) with plaque psoriasis 
conducted over a 15-day period , subjects were randomized to two groups, each 
completing either the paper or electronic PSI daily for 7 consecutive days 
followed by the alternate version. The disease specific Dermatology Life Quality 
Index [DLQI]) and the generic SF36v2 were also administered for evaluation of 
construct validity. Equivalence was assessed by the intraclass correlation 
coefficient (ICC) between both modes. Differences in scores between the 
administration modes were also tested using paired Student’s t-test. 
Measurement properties included internal consistency reliability, test-retest 
reliability, and construct validity. Convergent and discriminant validity were 
evaluated using pre-identified logical relationships between similar or distally 
related concepts. RESULTS: Eighty subjects (74% [59/80] moderate-to-severe 
psoriasis; 26% [21/80] mild psoriasis receiving systemic treatment) were enrolled 
from 8 sites in the United States. Seventeen (21%) subjects experienced a change 
in sPGA and were excluded from analyses. The paper and electronic modes of 
the PSI were highly concordant for both total scores (ICC = 0.969) and individual 
item scores (ICC range 0.934 to 0.965). Findings remained consistent (ICC values 
were all >0.91) irrespective of order of completion for the paper and electronic 
versions. All mean score differences were non-significant (p > 0.05) except for 
“flaking”; however, based on its reliability, validity, and clinical relevance, the 
item was retained. Minimum values for reliability (>0.70) and validity 
(convergent, r ≥ 0.30) were exceeded for the electronic PSI. CONCLUSIONS: 
Equivalence between paper and electronic versions of the PSI and the two 
modes’ comparable measurement properties indicated successful migration 
from paper to electronic format of the PSI.  
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OBJECTIVES: No standardized methods exist to measure outcomes related to 
Acute Bacterial Skin and Skin Structure Infections (ABSSSI). The purpose of this 
literature review was to identify clinical measurement concepts for other skin 
abnormalities that could be applied to ABSSSI. The results were used to inform 
the development of a standardized measurement tool and/or a novel Clinician 
Reported Outcome (ClinRO) for ABSSSI. METHODS: To identify relevant 
abstracts/articles for inclusion a search was conducted in OVID. MEDLINE (1946-
present) and EMBASE (1988-2012) were searched using terms related to ClinRO, 
measurement tools and devices, diagnostic tools, and skin 
diseases/abnormalities. RESULTS: The search identified 428 abstracts. 381 were 
excluded based on pre-specified criteria. The remaining 47 full-text articles were 
scrutinized for eligibility, resulting in 30 that met the inclusion criteria. No 
ABSSSI-specific ClinROs or measurement tools were identified in the literature. 
Several clinical concepts related to the measurement and evaluation of skin 
abnormalities were found e.g. Psoriasis Area and Severity Index; Vancouver Scar 
Scale; Pressure Ulcer Scale for Healing; Pressure Sore Status Tool and the Bates-
Jensen Wound Assessment Tool. Disease-severity instruments were also 
identified e.g. Severity Scoring of Atopic Dermatitis scale; Eczema Area and 
Severity Index; Investigators Global Assessment; Six Area, Six Sign Atopic 
Dermatitis severity index. Devices used to evaluate characteristics of skin 
abnormalities range from simple and inexpensive (ruler), to advanced and 
expensive (laser based tools). No single device was found that measures the full 
spectrum of a skin infection. CONCLUSIONS: There is a paucity of ABSSSI-
specific clinical endpoints/ClinRO measures in the existing literature. This 
review highlights the need to develop a standardized ClinRO instrument to 
assess clinical measurement concepts in ABSSSI. Robust scales, tools, and 
devices that measure or evaluate skin diseases and infections were identified. 
These could be considered when developing a standardized ABSSSI 
measurement tool and/or a novel ClinRO.  
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VALUING EQ-5D-5L: CAN LATENT UTILITIES DERIVED FROM A DISCRETE 
CHOICE MODEL BE TRANSFORMED TO HEALTH UTILITIES DERIVED FROM TIME 
TRADE-OFF TASKS?  
Xie F, Pullenayegum E 
McMaster University, Hamilton, ON, Canada  
OBJECTIVES: The EuroQol Group is evaluating the use of discrete choice 
experiments (DCEs) in valuing health states from the 5-level EQ-5D (EQ-5D-5L). 
Notably, a discrete choice (DC) model yields a latent utility that is ordinal and 
unbounded, whereas health utilities must have interval properties and be 
anchored at 0 (representing death) and 1 (representing full health). Latent 
utilities must therefore be transformed to health utilities. This pilot study 
investigated the feasibility of performing such a transformation. METHODS: 545 
respondents from Canada and 403 respondents from the UK each completed a 
series of DC and TTO tasks. Generalised linear mixed models were used to derive 
latent utilities. Linear regression models incorporating logarithmic and 
polynomial terms, as well as non-parametric LOESS and spline models were 
assessed as candidate functions for transforming the latent utilities onto the 
health utilities. RESULTS: There was a high correlation between health utilities 
measured through TTO tasks and latent utilities derived from modelling of DC 
data (Spearman rho of 0.79 in Canada and 0.86 in the UK). All transforming 
functions explained the between-state variation in health utilities, and, upon 
cross-validation, had minimal bias and small mean squared errors. Whilst the 
transformation functions derived through linear regression had the desirable 
feature of being monotone, the LOESS transform in Canada and the spline 
transform in the UK lacked monotonicity. CONCLUSIONS: This pilot study 
suggests that transforming latent utilities to health utilities is feasible, and 
provides preliminary evidence that linear regression involving polynomial and 
logarithmic terms may be more desirable than non-parametric spline or LOESS 
functions.  
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IS A PICTURE WORTH A THOUSAND WORDS? THE DEVELOPMENT OF A 
CLINICIAN AND PATIENT REPORTED PHOTONUMERIC GUIDE TO ASSESS SCAR 
SEVERITY  
Pleil A1, Jensen J1, Galipeau N2, Shields A2 
1Pfizer, Inc., San Diego, CA, USA, 2Adelphi Values, Boston, MA, USA  
OBJECTIVES: Photo-based questionnaires have been used to evaluate aesthetic 
treatment outcomes such as wrinkle reduction and eyelash growth. The 
objective of this study was to develop a photonumeric guide of scar severity 
intended for use by both clinicians and patients to measure scar treatment 
